Risk factors for treatment failure after allogeneic transplantation of patients with CLL : A report from the European Society for Blood and Marrow Transplantation

Autor: Schetelig, J., Wreede, L.C. de, Gelder, M. van, Andersen, N.S., Moreno, C., Vitek, A., Karas, M., Michallet, M., Machaczka, M., Gramatzki, M., Beelen, D., Finke, J., Delgado, J., Volin, L., Passweg, J., Dreger, P., Henseler, A., Biezen, A. van, Bornhauser, M., Schonland, S.O., Kroger, N., CLL Subcomm, Chronic Malignancies Working Party
Přispěvatelé: Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Oncology
Male
medicine.medical_treatment
Chronic lymphocytic leukemia
Medizin
Blood Donors
DISEASE
Targeted therapy
RETROSPECTIVE ANALYSIS
0302 clinical medicine
Risk Factors
hemic and lymphatic diseases
IDELALISIB
VENETOCLAX
Treatment Failure
IBRUTINIB
Age Factors
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Prognosis
3. Good health
030220 oncology & carcinogenesis
Cohort
SURVIVAL
Female
Adult
medicine.medical_specialty
Allogeneic transplantation
Risk Assessment
MECHANISMS
03 medical and health sciences
Young Adult
Sex Factors
Internal medicine
medicine
Humans
Transplantation
Homologous
Aged
Transplantation
Performance status
Proportional hazards model
business.industry
CHRONIC LYMPHOCYTIC-LEUKEMIA
STEM-CELL TRANSPLANTATION
medicine.disease
Leukemia
Lymphocytic
Chronic
B-Cell
Survival Analysis
Surgery
Graft-versus-host disease
business
FOLLOW-UP
030215 immunology
Zdroj: BONE MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bone Marrow Transplantation, 52(4), 552-560. Nature Publishing Group
Bone Marrow Transplantation, 52(4), 552-560
ISSN: 0268-3369
Popis: For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of non-relapse mortality (NRM) but a high risk of failure of targeted therapy may benefit most from alloHCT. We performed Cox regression analyses to identify risk factors for 2-year NRM and 5-year event-free survival (using EFS as a surrogate for long-term disease control) in a large, updated EBMT registry cohort (n = 694). For the whole cohort, 2-year NRM was 28% and 5-year EFS 37%. Higher age, lower performance status, unrelated donor type and unfavorable sex-mismatch had a significant adverse impact on 2-year NRM. Two-year NRM was calculated for good-and poor-risk reference patients. Predicted 2-year-NRM was 11 and 12% for male and female good-risk patients compared with 42 and 33% for male and female poor-risk patients. For 5-year EFS, age, performance status, prior autologous HCT, remission status and sex-mismatch had a significant impact, whereas del(17p) did not. The model-based prediction of 5-year EFS was 55% and 64%, respectively, for male and female good-risk patients. Good-risk transplant candidates with high-risk CLL and limited prognosis either on or after failure of targeted therapy should still be considered for alloHCT.
Databáze: OpenAIRE
Externí odkaz: